Key statistics
As of last trade Lisata Therapeutics Inc (8NE:MUN) traded at 2.68, -19.76% below its 52-week high of 3.34, set on Jun 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.68 |
---|---|
High | 2.68 |
Low | 2.68 |
Bid | 2.64 |
Offer | 2.76 |
Previous close | 2.68 |
Average volume | 59.11 |
---|---|
Shares outstanding | 8.32m |
Free float | 6.73m |
P/E (TTM) | -- |
Market cap | 24.88m USD |
EPS (TTM) | -2.56 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 07:04 BST.
More ▼
Announcements
- Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
- Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
- Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
- Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
- Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
- Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
- Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
- Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
- Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
More ▼